ORKA (Oruka Therapeutics) EBIT per Share : $ (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics EBIT per Share?

Oruka Therapeutics's EBIT per Share for the six months ended in Mar. 2024 was $0.00. Oruka Therapeutics does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Oruka Therapeutics's EBIT per Share or its related term are showing as below:

ORKA's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.1
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Oruka Therapeutics's EBIT for the six months ended in Mar. 2024 was $0.00 Mil.

Oruka Therapeutics EBIT per Share Historical Data

The historical data trend for Oruka Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics EBIT per Share Chart

Oruka Therapeutics Annual Data

Trend

Dec24

EBIT per Share

Oruka Therapeutics Semi-Annual Data
	Mar24
EBIT per Share	-

Oruka Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Oruka Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0	/	0
=	N/A

Oruka Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0	/	0
=	N/A

Oruka Therapeutics (NAS:ORKA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Oruka Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.